Pediatric Blood & Cancer

Cover image for Vol. 62 Issue 2

Edited By: Robert J. Arceci, M.D., Ph.D.

Impact Factor: 2.562

ISI Journal Citation Reports © Ranking: 2013: 21/118 (Pediatrics); 31/68 (Hematology); 113/203 (Oncology)

Online ISSN: 1545-5017



Author Guidelines


Wiley's Journal Styles

Submission and Contact Information
Pediatric Blood & Cancer welcomes submitted manuscripts online at: http://mc.manuscriptcentral.com/pbc. Authors are encouraged to check for an existing account. If you are submitting for the first time, and you do not have an existing account, then create a new account. Once you have logged in, you will be presented with the Main Menu and a link to your Author Center. Enter your Author Center to submit your manuscript. At the end of a successful submission, a confirmation screen with manuscript number will appear and you will receive an e-mail confirming that the manuscript has been received by the journal. If this does not happen, please check your submission and/or contact the Editorial Office. 

Editorial OfficeProduction Office
Julie Nash, Managing Editor
Emily Hammond, Editorial Office
205 Shannon Oaks Circle, Cary, NC 27511
Tel: 919-650-1459, ext. 219
Email: PBCeditorialoffice@wiley.com
Jennifer Chinworth
Tel: 703-352-0001, ext. 1154
Email: pbcprod@wiley.com


Requirements

All manuscripts submitted to Pediatric Blood & Cancer must be submitted solely to this journal, may not have been published in any part or form in another publication of any type, professional or lay, and become upon publication the property of the publisher. Any material reproduced or adapted from any other published or unpublished source must be duly acknowledged. It is the author's responsibility to obtain permission to reproduce copyrighted material. Upon submission of a manuscript for publication, the author will be requested to sign an agreement transferring copyright to the publisher, who reserves copyright. Material published in this journal may not be reproduced or published elsewhere without the written permission of the publisher and the author. All statements in, or omissions from, published manuscripts are the responsibility of the author who will assist the editor and publisher by reviewing proofs. All authors should have contributed in a significant manner (see Requirements for Authorship below) and be in agreement with all content in a manuscript. The corresponding author will take responsibility for this requirement being met.

No page charges will be levied against authors or their institutions for publication in this journal.

NOTE: Pediatric Blood & Cancer employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.

English Language Editing

Wiley suggests that authors from non-English speaking countries have their manuscript reviewed and corrected by English Language Services before submission.

1. Wiley’s English Editing Services: http://wileyeditingservices.com/en/

Please note that while this service will greatly improve the readability of your paper, it does not guarantee acceptance of your paper by the journal.

DISCLOSURE STATEMENT. All authors must disclose in a statement following Acknowledgments under the title, "Conflict of Interest Statement," any affiliations that they consider to be relevant and important with any organization that to any author's knowledge has a direct interest, particularly a financial interest, in the subject matter discussed. Such affiliations include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, a seat on the board of directors, or being publicly associated with a company or its products. Other areas of real or perceived conflict of interest would include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations. This requirement will apply to every sort of article submitted to the Journal, including original research, reviews, editorials, letters to the editor, and any others, and should be disclosed at the time of submission. The simplest remedy for conflict of interest is disclosure. It will not influence the editorial decision to accept or reject the manuscript. When an article is accepted for publication, the editors will discuss with the authors the manner in which such information is to be presented if additional questions arise.

I. INSTRUCTIONS TO AUTHORS

COVER LETTER. The online submission program requires an author cover letter. Please note that the cover letter should:

--Be addressed to the journal’s Editor-in-Chief;

--State what significant, new information the submission provides from that previously published in medical literature;

--Contain the manuscript title and all author names;

--Provide a brief summary of the findings and why they are important and appropriate for PBC;

--State what manuscript classification it fits, i.e., Research Article, Brief Report, etc;

--State that the manuscript has not been submitted elsewhere nor previously published;

--State any conflicts of interest;

--List names of 3 potential reviewers who: a) are experts in the field, b) are not from the authors’ institutions, and c) have no other conflicts of interest;

--State who and why any colleagues should not be asked to review, if applicable;

--State that all authors have contributed to the manuscript in significant ways, have reviewed and agreed upon the manuscript content.

FILE ORDER. When uploading the files into the ScholarOne Manuscript Central system, please order the files as follows:

1. Text file -Word file (.doc) should be 8.5 x 11 inches with at least 1 inch margins on all sides

2. Table files - Each table should be uploaded in a separate Word file in numerical order

3. Figure files - Each figure should be uploaded as a separate TIF or EPS file following in numerical order. Do not upload individual panels as separate files (e.g., “Figure 1a.tif” and “Figure 1b.tif.”).

4. Supplemental files - Please note that Supplemental files will be published in the exact format provided at submission.

5. For Revised Manuscripts, Responses to Review Comments should be included in the “View and Respond to Decision Letter” field of the online submission system.

6. For Resubmissions, Responses to Review Comments should be included in the cover letter, or as a Supplementary Material for Review file.

TITLE PAGE

--The complete title of the manuscript;

--The names and degrees of all authors (NOTE: While the number of authors should usually not exceed six, exceptions will be granted with adequate justification) that can be included in the cover letter.

--The complete affiliations of all authors;

--The name, address, phone, fax and email contact for the corresponding author;

--Word Count for:

a) Abstract (if applicable) and

b) Main Text (excludes title page, abstract, References, Tables, Figures);

--The number of Tables, Figures, and Supplemental files;

--A short running title (not to exceed 50 characters);

--Three to six keywords to index the content.

--An abbreviations key in a table. This should just be a two-column list, with the abbreviation on the left, and the full term or phrase on the right.

ABSTRACTS

--Abstracts should be included in the online submission form and in the manuscript file.

--Please do not include material in the Abstract that is not described in the main manuscript.

--See Article Types listing for specific formatting guidelines.

MAIN TEXT

--Double spaced with consecutive line numbering

--Font should 12pt in size, Times New Roman or Arial

--Order of elements: Title Page, Abstract, Introduction, Methods, Results, Discussion, Acknowledgements, Conflict of Interest statement, References, Legends

--ETHICS STATEMENT: If photographs include human subjects, the author must include an Ethics Statement in the main manuscript text, where approrpriate. This statement should affirm that informed consent has been properly documented. When possible, any identifiers in the image (such as facial features or patient ID numbers) should be obscured prior to review.

--Use subheadings and paragraph titles whenever possible. Note, however, that the Discussion section should not have separate subsections. Subheadings should not be underlined or be followed by punctuation.--No numbered or bulleted lists are allowed in the text file.

--See Journal Style section for further PBC style preferences.

REFERENCES

--Authors are responsible for the accuracy of references.

--Include the names of ALL authors. Do not use "et al".

--In the text, cite references consecutively as numerals in brackets, e.g., [1], [4-6], and [7, 8]. References should appear following the period at the end of a sentence.

--All references must be cited whether in text, figures or tables.

--Abstracts, unpublished data, and personal communications should not be listed as references.

--Provide all citations under a References heading, listed in numerical order.

--Include the complete title of the article and inclusive page numbers.

--Abbreviate journal names according to the National Library of Medicine: http://www.ncbi.nlm.nih.gov/nlmcatalog/journals

--Articles accepted for publication and published on-line should be referenced like a journal article, except that the DOI (digital object identifier) and the date of prepublication should supplant the year, volume number, and page numbers. The cited article must be accessible to readers. See examples 6-7 below.

--In the following examples, notice the punctuation and order of information, do not use all capitals, and do not underline:

Journal articles:
1. Plourde PV, Jeha S, Hijiya N, Keller FG, Silverman LB, Rheingold SR, Dreyer ZE, Dahl GV, Mercedes T. Lai C. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatric Blood Cancer 2014:61:1232–12389.

Books:
2. Cistaro A, editor. Atlas of PET/CT in Pediatric Patients. Milan: Springer.; 2014. 264 p.

Articles in Books:
3. Kurmasheva RT, Hosoi H, Kikuchi K, Houghton PJ. Molecular Therapy for Rhabdomyosarcoma. In: Houghton PJ, Arceci RJ. Molecularly Targeted Therapy for Childhood Cancer. New York: Springer; 2010: p. 425-458.

Online-Only Journal Articles:

4. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007:CD005166.
5. Willberg CW, Ward SM, Clayton RF, Naumov NV, McCormick C. Proto S. Harris M, Patel AH. Klenerman P. Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha. PloS ONE 2007;2:e791. doi:10.1371/journal.pone.0000791.

E-Pub Ahead of Print:
6. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2009; doi: 10.1136/guy.2006.107789.
7. Lindor, KD, Gores GA. Future course of hepatology research. Hepatology 2009; doi:10.1002/hep.22749.

Information from a URL:
8. Centers for Disease Control and Prevention. Viral hepatitis C fact sheet. Division of Viral Hepatitis home page. http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm. Published April 22, 2006, Accessed August 10, 2008.
9. Levin J. Viramidine phase III study-did not meet efficacy endpoint. Valeant looking at weight-based dosing of viramidine based on post-hoc analysis [NATAP conference report on Benhamou et al., J Hepatol 2006;44 (Suppl 2):S293.] http://www.natap.org/2006/EASL/EASL_19.htm. Accessed May 12, 2009.

TABLES

--Number tables consecutively with Roman numerals

--Do not include multi-part Tables (e.g., Table Ia, Ib, and Ic.)

--The table number, followed by a period, and title should be placed above the table.

Correct Example: Table I. Graph demonstrating results

Incorrect Example: Table 1: Graph demonstrating results

--Abbreviations should be in footnotes beneath the table, in paragraph form and not in lists.

Correct Example: a) Patient symptoms, b) Age at diagnosis

Incorrect Example: a) Patient symptoms
                                b) Age at diagnosis

FIGURES

--Figures should be numbered using Arabic numerals, i.e., Figure 1, Figure 2, etc., and cited in the manuscript as (Figure 1), (Figures 3A and 3B), etc.--The figure number and legend should be included in BOTH:

a) The legend list at the end of the manuscript AND

b) The Description field of the online submission form.

--Figures and text within a figure should not be surrounded by boxed lines. Crop extra white space from around images. Do not include legend text in the figure files.

--Please ensure that all axes are labeled clearly and in accordance with the journal's requirements for numbering (all numbers over 999 must contain commas, zeroes before decimals).

--Label each panel with a capital letter in the upper left corner

Panels should be labeled as A and B (not A. or A- or A).

--Upload figures as individual TIF or EPS files. High resolution PDF files may also be uploaded.

--Upload composite figures (with multiple panels) as one file. Do not upload separate panel files for a single figure.

--The journal requires a minimum resolution of 300dpi for all figures.

• 1200 DPI/PPI for black and white images, such as line drawings or graphs

• 300 DPI/PPI for picture-only photographs

• 600 DPI/PPI for photographs containing pictures and line elements, i.e., text labels, thin lines, arrows

--Please ensure that your figures are legible at 100% zoom in the file itself. We recommend that all text in figures be at least 6pt to ensure reviewer interpretation.

--Arrows should be included in radiographs or histology figures to point out areas of interest described in the figure legends below the figures.

--Any axis in a given figure must have a centered label. Note that numbers on the y-axis should be oriented to read left to right. For example:

chart

       

<img class="center-align" border="0" align="middle" alt="chart" src="pbc.axis.samplefigure.jpg" />

SUPPLEMENTARY MATERIAL

--Supplementary material will be published as submitted and will not be corrected or checked for scientific content, typographical errors or functionality. The responsibility for scientific accuracy and file functionality remains entirely with the authors. A disclaimer will be displayed to this effect with any supporting information published.

--Supplementary material should always be provided in its final format, as it will not be copyedited or changed from its original format. It will not be available for review prior to publication.

--Upload these files as either “Supplementary Material for Review” or “Supplementary Material NOT for Review,” as appropriate.

--For each individually uploaded supplementary file, a corresponding legend must be included in the manuscript file.

--Supplementary tables or figures may be made cited within the text (as Supplemental Table I and Supplemental Figure 1) and will be made available to readers online.

SPECIFIC JOURNAL STYLE GUIDELINES

--Either American or British style is acceptable.

American: use Merriam-Webster's; British: Oxford Shorter Dictionary.

--The statement ‘data not shown’ is not allowed within the manuscript text as readers cannot evaluate if the data are not shown. Such information should either be included in the manuscript or provided as a Supplementary Material for Review file.

--Please do not use slang expressions, such as “On the other hand”.

--Avoid statements such as “This is the first study…” and “To our knowledge…” and “this is the largest.” These expressions are not meaningful.

>>Name Formatting

--Disease names should be written without apostrophes, as follows: Wilms tumor, Burkitt lymphoma, Hodgkin disease, Ewing sarcoma.

--Abbreviations should be defined on first usage, then using of abbreviation alone is acceptable: e.g., Wilms Tumor (WT), then referred to as WT in subsequent mention, without quotation marks.

--Abbreviations should follow the guidelines in the CBE Style Manual, 5th Edition (available from the Council of Biology Editors, Inc., One Illinois Center, Suite 200, 111 East Wacker Drive, Chicago, IL60601-4298).

--Gene and protein designations should be written in the international style approved by the HUGO Gene Nomenclature Committee at http://www.genenames.org/guidelines.html

--Use uncapitalized generic names (e.g., cyclophosphamide) for all drugs and pharmaceutical preparations.

--Trade names (capitalized) for appliances, etc., may be used in the Methods section, and the manufacturers identified by name and location (city, state or country).

>>Human Subjects

--Please do not refer to patients by their diseases, e.g. “Wilms tumor patients” or “ALL patients.” Instead, identify them as “patients with Wilms tumor” and “patients with ALL.”

--Patients should be referred to only by subject numbers and not with names, initials, or other potentially identifying characters.

--Manuscripts reporting the results of experimental investigations on human subjects must include a statement to the effect that procedures had received official institutional approval.

--There should be no dates in the text or on radiographs as these are potential patient identifiers.

>>Numbers

--All measurements must be in metric units.

--Decimal numbers should have a zero preceding the decimal point (e.g., 0.95g).

--Decimal points should be periods and not commas.

--Do not begin sentences with a number. For example, it should be “Three patients…” instead of “3 patients…”

--Numbers over 999 must include a comma, e.g., 2,000.

II. ARTICLE TYPES

RESEARCH ARTICLES. Articles should represent original and in-depth studies involving any aspect of clinical or laboratory investigation.

Abstract: structured under headings (Background, Procedure, Results, and Conclusions. Length should be 250 words or less.

Length: 3,500 word maximum (excludes title page, Abstract, References, Tables, Figures.) References: 50 or fewer

Figures/Tables: The number combined should be not be greater than 6 (excluding supplemental material). Tables and figures should not simply repeat information in the text.

PRIORITY REPORTS. At the recommendation of the journal’s Editor-in-Chief and with recommendations from members of the Editorial Board, certain high-impact research articles will selected to be fast-tracked for online publication within 4 weeks after final acceptance and print publication within 2 months of final acceptance. Cover letters for articles submitted as Priority Reports should include an explanation as to the reason for this designation.

Abstract: Structured, 150 word maximum

Length: 2,000 word maximum References: 50 or fewer Figures/Tables: The number combined should not be more than 4 (excluding Supplemental Material).

Tables and figures should not simply repeat information in the text. .

BRIEF REPORTS. Brief reports may include descriptions of single or several patients that demonstrate novel findings or add in a significant way to already existing literature. Brief reports may also include novel laboratory observations relating to clinical questions or advances in laboratory methodologies. Brief reports should include the following sections: Introduction, Results (including Methods or Case Descriptions), and Discussion. Abstract: 100 word maximum; unstructured

Length: 1,200 word maximum (excludes the title page, abstract, references, tables, figures)

References: 20 or fewer

Figures/Tables: The number combined should be not be greater than 2 (excluding supplemental material). Tables and figures should not simply repeat information in the text.

CRITICAL REVIEWS. Reviews of important and timely subjects can be invited through the Editorial Board or submitted after a brief introduction to the Editor-in-Chief. Authors should consult the editor prior to submission by e-mailing PBCeditorialoffice@wiley.com. Reviews should focus on the critical aspects of a subject, linking what is known to what areas remain controversial or unanswered. Historical accounts of important events relating to pediatric hematology/oncology are also acceptable. Requests for permission to submit manuscripts of greater length should be emailed to the Editor-in-Chief prior to submission.

Abstract: 100 word maximum; unstructured

Length: 3,500 word maximum

References: 100 or fewer

Figures/Tables: Illustrations and tables should be used only to provide summaries or a synthesis of ideas and/or data not included in the text.

REVIEWS OF BOOKS AND OTHER MEDIA FORMATS. Reviews of books, films or other media formats relevant to the scientific or clinical practice of medicine with particular importance to pediatric hematology/oncology can be invited or submitted independently. In the latter case, consultation with the Editor-in-Chief should be made prior to submission.

Length: 1,000 word maximum .

CORRESPONDENCE AND LETTERS. Letters to the Editor should usually be in reference to previously published manuscripts in Pediatric Blood and Cancer. Correspondence relating to important and timely publications or topics from other sources and brief descriptions of interesting laboratory or clinical observations may also be appropriate.

Length: 500 word maximum

Figures/Tables: Illustrations or tables should only be included when absolutely necessary; maximum of 1 total.

References: 10 or fewer

HIGHLIGHTS. Highlights are submitted only at the invitation of the Editor-in-Chief. These will summarize findings from a recently accepted paper and put them into perspective in terms of past work and future challenges. Controversial areas should be included.

Length: 1,000 word maximum

References: 10 or fewer

COMMENTARY. Commentaries are usually invited but may be submitted independently after consultation with the Editor-in-Chief. Commentaries should focus on a controversial subject arising from a recently published Pediatric Blood & Cancer manuscript but may also focus on independent and timely topics of relevance to the journal’s readership. Commentaries will be reviewed and may require changes or be rejected.

Length: 1,200 word maximum

References: 10 or fewer

Figures/Tables: Include only if they highlight or clarify points made in the text.

MEETING REPORTS AND SUPPLEMENTS. Concise summaries of meetings that have important information to convey to the readers of
Pediatric Blood & Cancer are welcomed but consultation with the Editor-in-Chief should occur before submission. Summaries should emphasize the issues discussed at the meeting along with why they are important or controversial. More extensive meeting reports with manuscripts from the speakers at the meeting are also welcomed but early consultation with the Editor-in-Chief must take place in order to determine the type and number of manuscripts, expected pages to be published, and the review process, as well as procurement of additional funding if required.

Length: 1,500 word maximum

Figures/Tables: Include only if they highlight or clarify points made in the text. .

HISTORICAL PERSPECTIVE. A Historical Perspective should be submitted only after consultation with the journal’s Editor-in-Chief. This occasionally-appearing series focuses on the history of pediatric hematology/oncology.

Length: 1,500 word maximum

References: 20 or fewer

Figures/Tables: No more than 2 figures or tables combined.

SPECIAL REPORT. To be submitted only after consultation with the journal’s Editor-in-Chief, the report should focus on a subject of current interest in developing countries.

Abstract: 100 word maximum; unstructured

Length: 2,500 word maximum

References: 20 or fewer

Figures/Tables: No more than 2 figures or tables combined.

CLINICAL PRACTICE GUIDELINES (CPG) should concern important and timely subjects. They must receive pre-submission approval from the Editor-in-Chief. CPGs should be based on the best available evidence with documentation of the level of evidence. The Institute of Medicine has defined a CPG as a "systematically developed statement to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances." An excellent resource for preparing a CPG is the manuscript by Turner et al., Development of evidence-based clinical practice guidelines (CPG's: comparing approaches, Implementation Science, 3:1-8; 2008. http://www.implementationscience.com/content/pdf/1748-5908-3-45.pdf

Abstract: 100 word maximum; unstructured

Length: 4,500 word maximum

References: 150 or fewer

Figures/Tables: Illustrations, tables, and clinical care algorithms are encouraged to augment the text.

MEETING ABSTRACTS

*Abstract text should be 300 words or less. That word count excludes the abstract title, author names and affiliations.

*There should be 4 sections to the abstract: Background/Objectives, Design/Methods, Results, Conclusion. All text should be included in a single paragraph and contain no lists.

*Abstract text should be written in complete sentences and in correct English.

*There should be a period at the end of all sentences.

*Tables and figures, only when critical to the content, should be included and must comply with PBC Author Guideline format.

*Abstract titles should be in all capital letters, e.g., INDUCTION OUTCOMES IN CHILDREN WITH ALL

*Author names should be listed below the abstract title and underlined. The first and last names of authors should be written in upper and lower case letters and should be underlined. No degrees of authors should be included.

*Author affiliations should be written in upper and lower case letters, e.g., Tata Memorial Centre

*Geographic location should be indicated by city and country, with state, province, or other subdivision added if necessary for disambiguation, e.g. London, UK; but Portland, OR, USA. Names of cities and countries with 2 words should be written in upper and lower case letters, e.g., Czech Republic, South Africa, Los Angeles, St. Louis. Common abbreviations may be used, e.g. UK, USA.

*Periods should be used in numbers for decimal points, not commas, e.g., P=0.015, and numbers beginning with a decimal point should be preceded by a zero.

*Disease names should be written without apostrophes, e.g., Hodgkin lymphoma, Non-Hodgkin lymphoma, Burkitt lymphoma, Ewing sarcoma

*Numbers containing more than 3 digits should have a comma, e.g., 3,000.

*Abbreviations should be defined on first usage, then using of abbreviation alone is acceptable: e.g., Wilms Tumor (WT), then referred to as WT in subsequent mention, no quotation marks, however.

*Abstracts need to be proofread for all spelling and grammatical errors.

*Abstracts that do not satisfy publication instructions will not be published.

CLINICAL TRIALS

- Reporting prospectively conducted trials is strongly encouraged and such trials will be prioritized

- Retrospective reporting of clinical data on patients are potentially acceptable for publication. They need to comply with documentation of approval by an institutional ethical review board or equivalent.

- All manuscripts reporting clinical trials need to document that the trial or study was approved Institutional Review Board or equivalent.

- All manuscripts reporting clinical trials need to be registered with ‘ClinicalTrials.Gov’ and/or an equivalent site.

NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement

Wiley Author Licensing Services (WALS)

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp

For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

For additional tools visit Author Resources - an enhanced suite of online tools for Wiley Online Library journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools. 

SEARCH

SEARCH BY CITATION